Potential of glutamate-based drug discovery for next generation antidepressants

Pharmaceuticals

Volumn 8, Issue 3, 2015, Pages 590-606

  Chaki, Shigeyuki ^a   Fukumoto, Kenichi ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

GluN2B antagonist; GLYX 13; Ketamine; mGlu2 3 antagonist; mGlu5 antagonist

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; ADX 88178; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; BASIMGLURANT; BCI 838; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GRN 529; HYDROXYNORKETAMINE; KETAMINE; LANICEMINE; LITHIUM; MEMANTINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR ANTAGONIST; MIDAZOLAM; MK 0657; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N,N' DIBENZHYDRYLETHYLENEDIAMINE; RAPASTINEL; SCOPOLAMINE; SEROTONIN RECEPTOR; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BIPOLAR DEPRESSION; CLINICAL STUDY; DEPRESSION; DRUG DEVELOPMENT; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; HUMAN; MAJOR DEPRESSION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SYNAPTIC TRANSMISSION; TREATMENT RESISTANT DEPRESSION; UNSPECIFIED SIDE EFFECT;

EID: 84941959288     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph8030590     Document Type: Review

References (85)

1. Diazgranados, N.; Ibrahim, L.A.; Brutsche, N.E.; Ameli, R.; Henter, I.D.; Luckenbaugh, D.A.; Machado-Vieira, R.; Zarate, C.A., Jr. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry 2010, 71, 1605-1611.
2. Ibrahim, L.; Diazgranados, N.; Luckenbaugh, D.A.; Machado-Vieira, R.; Baumann, J.; Mallinger, A.G.; Zarate, C.A., Jr. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35, 1155-1159.
3. Murrough, J.W.; Iosifescu, D.V.; Chang, L.C.; Al Jurdi, R.K.; Green, C.E.; Perez, A.M.; Iqbal, S.; Pillemer, S.; Foulkes, A.; Shah, A.; et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am. J. Psychiatry 2013, 170, 1134-1142.
4. Price, R.B.; Nock, M.K.; Charney, D.S.; Mathew, S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 2009, 66, 522-526.
5. Zarate, C.A., Jr.; Singh, J.B.; Carlson, P.J.; Brutsche, N.E.; Ameli, R.; Luckenbaugh, D.A.; Charney, D.S.; Manji, H.K. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63, 856-864.
6. Diazgranados, N.; Ibrahim, L.; Brutsche, N.E.; Newberg, A.; Kronstein, P.; Khalife, S.; Kammerer, W.A.; Quezado, Z.; Luckenbaugh, D.A.; Salvadore, G.; Machado-Vieira, R.; Manji, H.K.; Zarate, C.A., Jr. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010, 67, 793-802.
7. Zarate, C.A., Jr.; Brutsche, N.E.; Ibrahim, L.; Franco-Chaves, J.; Diazgranados, N.; Cravchik, A.; Selter, J.; Marquardt, C.A.; Liberty, V.; Luckenbaugh, D.A. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry 2012, 71, 939-946.
8. Ibrahim, L.; Diaz Granados, N.; Jolkovsky, L.; Brutsche, N.; Luckenbaugh, D.A.; Herring, W.J.; Potter, W.Z.; Zarate, C.A., Jr. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J. Clin. Psychopharmacol. 2012, 32, 551-557.
9. Preskorn, S.H.; Baker, B.; Kolluri, S.; Menniti, F.S.; Krams, M.; Landen, J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 2008, 28, 631-637.
10. Preskorn, S.; Macaluso, M.; Mehra, D.O.; Zammit, G.; Moskal, J.R.; Burch, R.M.; GLYX-13 Clinical Study Group. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J. Psychiatr. Pract. 2015, 21, 140-149.
11. Sanacora, G.; Smith, M.A.; Pathak, S.; Su, H.L.; Boeijinga, P.H.; McCarthy, D.J.; Quirk, M.C. Lanicemine: A low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol. Psychiatry 2014, 19, 978-985.
12. Zarate, C.A., Jr.; Mathews, D.; Ibrahim, L.; Chaves, J.F.; Marquardt, C.; Ukoh, I.; Jolkovsky, L.; Brutsche, N.E.; Smith, M.A.; Luckenbaugh, D.A. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol. Psychiatry 2013, 74, 257-264.
13. Berman, R.M.; Cappiello, A.; Anand, A.; Oren, D.A.; Heninger, G.R.; Charney, D.S.; Krystal, J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47, 351-354.
14. aan het Rot, M.; Collins, K.A.; Murrough, J.W.; Perez, A.M.; Reich, D.L.; Charney, D.S.; Mathew, S.J. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry 2010, 67, 139-145.
15. Murrough, J.W.; Perez, A.M.; Pillemer, S.; Stern, J.; Parides, M.K.; aan het Rot, M.; Collins, K.A.; Mathew, S.J.; Charney, D.S.; Iosifescu, D.V. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol. Psychiatry 2013, 74, 250-256.
16. Rasmussen, K.G.; Lineberry, T.W.; Galardy, C.W.; Kung, S.; Lapid, M.I.; Palmer, B.A.; Ritter, M.J.; Schak, K.M.; Sola, C.L.; Hanson, A.J.; Frye, M.A. Serial infusions of low-dose ketamine for major depression. J. Psychopharmacol. 2013, 27, 444-450.
17. Sinner, B.; Graf, B.M. Ketamine. Handb. Exp. Pharmacol. 2008, 182, 313-333.
18. Abdallah, C.G.; Sanacora, G.; Duman, R.S.; Krystal, J.H. Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics. Annu. Rev. Med. 2015, 66, 509-523.
19. Duman, R.S.; Li, N.; Liu, R.J.; Duric, V.; Aghajanian, G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012, 62, 35-41.
20. Krystal, J.H.; Sanacora, G.; Duman, R.S. Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond. Biol. Psychiatry. 2013, 73, 1133-1141.
21. Autry, A.E.; Adachi, M.; Nosyreva, E.; Na, E.S.; Los, M.F.; Cheng, P.F.; Kavalali, E.T.; Monteggia, L.M. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475, 91-95.
22. Koike, H.; Fukumoto, K.; Iijima, M.; Chaki, S. Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression. Behav. Brain Res. 2013, 238, 48-52.
23. Liu, R.J.; Lee, F.S.; Li, X.Y.; Bambico, F.; Duman, R.S.; Aghajanian, G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 2012, 71, 996-1005.
24. Laje, G.; Lally, N.; Mathews, D.; Brutsche, N.; Chemerinski, A.; Akula, N.; Kelmendi, B.; Simen, A.; McMahon, F.J.; Sanacora, G.; Zarate, C., Jr. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol. Psychiatry 2012, 72, e27-e28.
25. Fuchikami, M.; Thomas, A.; Liu, R.; Wohleb, E.S.; Land, B.B.; DiLeone, R.J.; Aghajanian, G.K.; Duman, R.S. Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions. Proc. Natl. Acad. Sci. U.S.A. 2015, 112, 8106-8111.
26. Li, N.; Lee, B.; Liu, RJ.; Banasr, M.; Dwyer, J.M.; Iwata, M.; Li, X.Y.; Aghajanian, G.; Duman, R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329, 959-964.
27. Maeng, S.; Zarate, C.A., Jr.; Du, J.; Schloesser, R.J.; McCammon, J.; Chen, G.; Manji, H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 2008, 63, 349-352.
28. Pozzi, L.; Dorocic, I.P.; Wang, X.; Carlén, M.; Meletis, K. Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists. PLoS ONE 2014, 9, e83879.
29. Kiselycznyk, C.; Jury, N.J.; Halladay, L.R.; Nakazawa, K.; Mishina, M.; Sprengel, R.; Grant, S.G.; Svenningsson, P.; Holmes, A. NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism. Behav. Brain Res. 2015, 287, 89-95.
30. Miller, O.H.; Yang, L.; Wang, C.C.; Hargroder, E.A.; Zhang, Y.; Delpire, E.; Hall, B.J. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. Elife 2014, 3, e03581.
31. Loix, S.; De Kock, M.; Henin, P. The anti-inflammatory effects of ketamine: state of the art. Acta. Anaesthesiol. Belg. 2011, 62, 47-58.
32. Yang, C.; Shen, J.; Hong, T.; Hu, T.T.; Li, Z.J.; Zhang, H.T.; Zhang, Y.J.; Zhou, Z.Q.; Yang, J.J. Effects of ketamine on lipopolysaccharide-induced depressive-like behavior and the expression of inflammatory cytokines in the rat prefrontal cortex. Mol. Med. Rep. 2013, 8, 887-890.
33. Wu, Y.; Li, W.; Zhou, C.; Lu, F.; Gao, T.; Liu, Y.; Cao, J.; Zhang, Y.; Zhang, Y.; Zhou C. Ketamine inhibits lipopolysaccharide-induced astrocytes activation by suppressing TLR4/NF-ĸB pathway. Cell Physiol. Biochem. 2012, 30, 609-617.
34. Ménard, C.; Hodes, G.E.; Russo, S.J. Pathogenesis of depression: Insights from human and rodent studies. Neuroscience 2015, doi:10.1016/j.neuroscience.2015.05.053.
35. Walker, A.K.; Budac, D.P.; Bisulco, S.; Lee, A.W.; Smith, R.A.; Beenders, B.; Kelley, K.W.; Dantzer, R. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 2013, 38, 1609-1616.
36. Domino, E.F. Taming the ketamine tiger. 1965. Anesthesiology 2010, 113, 678-684.
37. Kohrs, R.; Durieux, M.E. Ketamine: Teaching an old drug new tricks. Anesth. Analg. 1998, 87, 1186-1193.
38. Zhang, J.C.; Li, S.X.; Hashimoto, K. R(−)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol. Biochem. Behav. 2014, 116, 137-141.
39. Mion, G.; Villevieille, T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci. Ther. 2013, 19, 370-380.
40. Desta, Z.; Moaddel, R.; Ogburn, E.T.; Xu, C.; Ramamoorthy, A.; Venkata, S.L.; Sanghvi, M.; Goldberg, M.E.; Torjman, M.C.; Wainer, I.W. Stereoselective and regiospecific hydroxylation of ketamine and norketamine. Xenobiotica. 2012, 42, 1076-1087.
41. Zarate, C.A., Jr.; Brutsche, N.; Laje, G.; Luckenbaugh, D.A.; Venkata, S.L.; Ramamoorthy, A.; Moaddel, R.; Wainer, I.W. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol. Psychiatry 2012, 72, 331-338.
42. Singh, N.S.; Zarate, C.A., Jr.; Moaddel, R.; Bernier, M.; Wainer, I.W. What is hydroxynorketamine and what can it bring to neurotherapeutics? Expert Rev. Neurother. 2014, 14, 1239-1242.
43. Paul, R.K.; Singh, N.S.; Khadeer, M.; Moaddel, R.; Sanghvi, M.; Green, C.E.; O'Loughlin, K.; Torjman, M.C.; Bernier, M.; Wainer, I.W. (R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function. Anesthesiology 2014, 121, 149-159.
44. Weed, M.R.; Bookbinder, M.; Polino, J.; Keavy, D.; Cardinal, R.N.; Simmermacher-Mayer, J.; Cometa, F.N.; King, D.; Thangathirupathy, S.; Macor, J.E.; Bristow, L.J. Negative allosteric modulators selective for the NR2B subtype of the NMDA receptor impair cognition in multiple domains. Neuropsychopharmacology 2015, doi:10.1038/npp.2015.184.
45. Mealing, G.A.; Lanthorn, T.H.; Murray, C.L.; Small, D.L.; Morley, P. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J. Pharmacol. Exp. Ther. 1999, 288, 204-210.
46. Sanacora, G.; Schatzberg, A.F. Ketamine: Promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 2015, 40, 259-267.
47. Burgdorf, J.; Zhang, X.L.; Nicholson, K.L.; Balster, R.L.; Leander, J.D.; Stanton, P.K.; Gross, A.L.; Kroes, R.A.; Moskal, J.R. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 2013, 38, 729-742.
48. Huang, C.C.; Wei, I.H.; Huang, C.L.; Chen, K.T.; Tsai, M.H.; Tsai, P.; Tun, R.; Huang, K.H.; Chang, Y.C.; Lane, H.Y.; Tsai, G.E. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol. Psychiatry 2013, 74, 734-741.
49. Zarate, C.A., Jr.; Singh, J.B.; Quiroz, J.A.; De Jesus, G.; Denicoff, K.K.; Luckenbaugh, D.A.; Manji, H.K.; Charney, D.S. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am. J. Psychiatry 2006, 163, 153-155.
50. Gideons, E.S.; Kavalali, E.T.; Monteggia, L.M. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 8649-8654.
51. Chiu, C.T.; Scheuing, L.; Liu, G.; Liao, H.M.; Linares, G.R.; Lin, D.; Chuang, D.M. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Int. J. Neuropsychopharmacol. 2014, 18, pii: pyu102.
52. Liu, R.J.; Fuchikami, M.; Dwyer, J.M.; Lepack, A.E.; Duman, R.S.; Aghajanian, G.K. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 2013, 38, 2268-2277.
53. Chaki, S.; Yoshikawa, R.; Hirota, S.; Shimazaki, T.; Maeda, M.; Kawashima, N.; Yoshimizu, T.; Yasuhara, A.; Sakagami, K.; Okuyama, S.; Nakanishi, S.; Nakazato, A. MGS0039: A potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity., Neuropharmacology 2004, 46, 457-467.
54. Kawasaki, T.; Ago, Y.; Yano, K.; Araki, R.; Washida, Y.; Onoe, H.; Chaki, S.; Nakazato, A.; Hashimoto, H.; Baba, A.; Takuma, K.; Matsuda, T. Increased binding of cortical and hippocampal group II metabotropic glutamate receptors in isolation-reared mice. Neuropharmacology 2011, 60, 397-404.
55. Pałucha-Poniewiera, A.; Wierońska, JM.; Brański, P.; Stachowicz, K.; Chaki, S.; Pilc, A. On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology (Berl.) 2010, 212, 523-535.
56. Yoshimizu, T.; Shimazaki, T.; Ito, A.; Chaki, S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl.) 2006, 186, 587-593.
57. Dwyer, J.M.; Lepack, A.E.; Duman, R.S. mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. J. Mol. Psychiatry 2013, 1, 15.
58. Koike, H.; Iijima, M.; Chaki, S. Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats. Pharmacol. Biochem. Behav. 2013, 107, 20-23.
59. Dwyer, J.M.; Lepack, A.E.; Duman, R.S. mTOR activation is required for the antidepressant effects of mGluR2/3 blockade., Int. J. Neuropsychopharmacol. 2012, 15, 429-434.
60. Hascup, E.R.; Hascup, K.N.; Stephens, M.; Pomerleau, F.; Huettl, P.; Gratton, A.; Gerhardt, G.A. Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex. J. Neurochem. 2010, 115, 1608-1620.
61. Koike, H.; Iijima, M.; Chaki, S. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists., Neuropharmacology 2011, 61, 1419-1423.
62. Fukumoto, K.; Iijima, M.; Chaki, S. Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test. Psychopharmacology (Berl.) 2014, 231, 2291-2298.
63. Gigliucci, V.; O'Dowd, G.; Casey, S.; Egan, D.; Gibney, S.; Harkin, A. Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. Psychopharmacology (Berl.) 2013, 228, 157-166.
64. Gradient, R.A.; Wedel, P.C.; Frisbie, V.M.; Leuchter, A.F.; Targum, S.D.; Truong, C.T.; Hutchinson, J.H. Safety, pharmacokinetic and pharmacodynamics profile of BCI-632, a selective metabotropic glutamate 2/3 receptor antagonist, in healthy human subjects. Abstr. Neurosci. Meeting 2012, 42, 20.
65. Belozertseva, I.V.; Kos, T.; Popik, P.; Danysz, W.; Bespalov, A.Y. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur. Neuropsychopharmacol. 2007, 17, 172-179.
66. Hughes, Z.A.; Neal, S.J.; Smith, D.L.; Rizzo, S.S.; Pulicicchio, C.M.; Lotarski, S.; Lu, S.; Dwyer, J.M.; Brennan, J.; Olsen, M.; et al. Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. Neuropharmacology 2013, 66, 202-214.
67. Pałucha, A.; Brański, P.; Szewczyk, B.; Wierońska, J.M.; Kłak, K.; Pilc, A. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol. Biochem. Behav. 2005, 81, 901-906.
68. Pilc, A.; Kłodzińska, A.; Brański, P.; Nowak, G.; Pałucha, A.; Szewczyk, B.; Tatarczyńska, E.; Chojnacka-Wójcik, E.; Wierońska, J.M. Multiple MPEP administrations evoke anxiolytic-and antidepressant-like effects in rats. Neuropharmacology 2002, 43, 181-187.
69. Li, X.; Need, A.B.; Baez, M.; Witkin, J.M. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J. Pharmacol. Exp. Ther. 2006, 319, 254-259.
70. Chaki, S.; Ago, Y.; Palucha-Paniewiera, A.; Matrisciano, F.; Pilc, A. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 2013, 66, 40-52.
71. Pałucha-Poniewiera, A.; Brański, P.; Wierońska, J.M.; Stachowicz, K.; Sławińska, A.; Pilc, A. The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent. Psychopharmacology (Berl.) 2014, 231, 97-107.
72. Fukumoto, K.; Chaki, S. Involvement of serotonergic system in the effect of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test. J. Pharmacol. Sci. 2015, 127, 57-61.
73. Quiroz, J.A.; Tamburri, P.; Deptula, D.; Banken, L.; Beyer, U.; Fontoura, P.; Santarelli, L. The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomised, double-blind, placebo-controlled study. In Abstracts of the 27th Congress of the European College of Neuropsychopharmacology, Berlin, 18-21 October 2014, P.2.f.027.
74. Podkowa, K.; Rzeźniczek, S.; Marciniak, M.; Acher, F.; Pilc, A.; Pałucha-Poniewiera, A. A novel mGlu4 selective agonist LSP4-2022 increases behavioral despair in mouse models of antidepressant action. Neuropharmacology 2015, 97, 338-345.
75. Kalinichev, M.; Le Poul, E.; Boléa, C.; Girard, F.; Campo, B.; Fonsi, M.; Royer-Urios, I.; Browne, S.E.; Uslaner, J.M.; Davis, M.J.; Raber, J.; Duvoisin, R.; Bate, S.T.; Reynolds, I.J.; Poli, S.; Celanire, S. Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders. J. Pharmacol. Exp. Ther. 2014, 350, 495-505.
76. Sławińska, A.; Wierońska, J.M.; Stachowicz, K.; Pałucha-Poniewiera, A.; Uberti, M.A.; Bacolod, M.A.; Doller, D.; Pilc, A. Anxiolytic-but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu4 receptor. Neuropharmacology 2013, 66, 225-235.
77. Wierońska, J.M.; Stachowicz, K.; Pałucha-Poniewiera, A.; Acher, F.; Brański, P.; Pilc, A. Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressantlike activity, mediated by serotonergic and GABAergic systems. Neuropharmacology 2010, 59, 627-634.
78. O'Connor, R.M.; Cryan, J.F. The effects of mGlu₇ receptor modulation in behavioural models sensitive to antidepressant action in two mouse strains. Behav. Pharmacol. 2013, 24, 105-113.
79. Pałucha-Poniewiera, A.; Brański, P.; Lenda, T.; Pilc, A. The antidepressant-like action of metabotropic glutamate 7 receptor agonist N,N'-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent. J. Pharmacol. Exp. Ther. 2010, 334, 1066-1074.
80. Palucha, A.; Klak, K.; Branski, P.; van der Putten, H.; Flor, P.J.; Pilc, A. Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology (Berl.) 2007, 194, 555-562.
81. Pałucha-Poniewiera, A.; Pilc, A. A selective mGlu7 receptor antagonist MMPIP reversed antidepressant-like effects of AMN082 in rats. Behav. Brain Res. 2013, 238, 109-112.
82. Pałucha-Poniewiera, A.; Szewczyk, B.; Pilc, A. Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats. Neuropharmacology 2014, 82, 59-68.
83. Cryan, J.F.; Kelly, P.H.; Neijt, H.C.; Sansig, G.; Flor, P.J.; van Der Putten, H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur. J. Neurosci. 2003, 17, 2409-2417.
84. Drevets, W.C.; Zarate, C.A., Jr.; Furey, M.L. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: A review. Biol. Psychiatry 2013, 73, 1156-1163.
85. Voleti, B.; Navarria, A.; Liu, R.J.; Banasr, M.; Li, N.; Terwilliger, R.; Sanacora, G.; Eid, T.; Aghajanian, G.; Duman, R.S. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol. Psychiatry 2013, 74, 742-749.